CRNX Crinetics Pharmaceuticals, Inc.
FY2025 10-K
Crinetics Pharmaceuticals, Inc. (CRNX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Discovery, development, commercialization of novel small molecule GPCR-targeted therapies for endocrine diseases and endocrine-related tumors
- • New product: FDA approved PALSONIFY (paltusotine) in September 2025, first once-daily oral treatment for acromegaly adults inadequately managed by surgery
Management Discussion & Analysis
- • Revenue $7.7M in 2025 vs $1.0M in 2024, driven by $5.4M product sales from PALSONIFY launch
- • Operating margin -681.9% in 2025 vs -326.4% in 2024 (loss from ops $516.8M vs $338.9M on $7.7M vs $1.0M revenue)
Risk Factors
- • FDA approval risk: PALSONIFY regulatory compliance including U.S. FDA and EMA submissions with risk of delays or denial
- • Geopolitical risk: exposure to market disruptions from international conflicts including Russia-Ukraine and Middle East tensions
Financial SummaryXBRL
Revenue
$8M
Net Income
-$465M
Operating Margin
-6714.8%
Net Margin
-6046.2%
ROE
-46.9%
Total Assets
$1.1B
EPS (Diluted)
$-4.95
Operating Cash Flow
-$378M
Source: XBRL data from Crinetics Pharmaceuticals, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Crinetics Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.